Pharmacologic Treatments for COVID-19

During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2

Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.

Committee Members
Speaker at Drug Delivery Events - Vladlen Slepak

Vladlen Slepak

University of Miami Miller School of Medicine, United States
Speaker at Drug Delivery Events - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at Pharmaceutical Conference - Consolato M Sergi

Consolato M Sergi

Universities of Alberta and Ottawa, Canada
Speaker at Drug Delivery Events - Huiqin Yang

Huiqin Yang

ICON Clinical Research Ltd, United Kingdom

Submit your abstract Today

Youtube
Watsapp